drugset / Trial / NCT00933205

An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.

NCT00933205 ↗

Expanded access Approved for marketing Boehringer Ingelheim

Summary

The purpose of this Open Label Safety Study is to provide access to and evaluate the safety and tolerability of TPV/r in treatment-experienced patients with advanced HIV-1 infection who have failed at least two PI-containing regimens, and have limited treatment options.

Timeline

Start
2004-05
Primary completion
2008-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Tipranavir Small molecule — —